Warfarin, a vitamin K antagonist, is widely used as an anticoagulant for the prevention and treatment of thrombotic diseases. However, it has substantial limitations, such as bleeding and poorly controlled levels of anticoagulation in patients. Thus, intensive effort has been focused on developing more specific inhibitors of the coagulation enzymes thrombin and fXa. Several of these new agents have been approved for the prevention of stroke in patients with atrial fibrillation, prevention of venous thromboembolism after orthopedic surgery and treatment of deep vein thrombosis or pulmonary embolism [1] [2] [3] [4] . Randomized clinical trials have established that these new agents share the bleeding liability of warfarin and parenteral anticoagulants such as heparin. With a worldwide aging population leading to an increase in the prevalence of atrial fibrillation and a broader use of anticoagulants, the management of bleeding complications in frail elderly patients represents an unmet need in clinical practice.
Warfarin, a vitamin K antagonist, is widely used as an anticoagulant for the prevention and treatment of thrombotic diseases. However, it has substantial limitations, such as bleeding and poorly controlled levels of anticoagulation in patients. Thus, intensive effort has been focused on developing more specific inhibitors of the coagulation enzymes thrombin and fXa. Several of these new agents have been approved for the prevention of stroke in patients with atrial fibrillation, prevention of venous thromboembolism after orthopedic surgery and treatment of deep vein thrombosis or pulmonary embolism [1] [2] [3] [4] . Randomized clinical trials have established that these new agents share the bleeding liability of warfarin and parenteral anticoagulants such as heparin. With a worldwide aging population leading to an increase in the prevalence of atrial fibrillation and a broader use of anticoagulants, the management of bleeding complications in frail elderly patients represents an unmet need in clinical practice.
Traditional anticoagulants have antidotes. Heparin can be neutralized by protamine, and warfarin anticoagulation can be reversed by vitamin K injections. Protamine can also partially reverse the effect of ATIII-dependent low-molecular weight heparins (LMWH) such as enoxaparin but has no corrective activity on shorter heparins (fondaparinux or idraparinux) [5] [6] [7] . Fresh frozen plasma, prothrombincomplex concentrate and recombinant factor VIIa have also been used as generic hemostatic agents in patients treated with anticoagulants who experience major trauma or severe hemorrhage [8] [9] [10] . However, the effectiveness of these nonspecific agents has not been established in blinded clinical trials.
As direct oral fXa inhibitors such as rivaroxaban and apixaban have the potential to become a mainstay of anticoagulant therapy, we have designed a recombinant protein as a universal antidote to this class of drugs. This specific antidote for fXa inhibitors is a truncated form of enzymatically inactive fXa. The modified recombinant protein (r-Antidote, PRT064445) lacks a membrane-binding γ-carboxyglutamic acid (GLA) domain and is catalytically inactive because of a mutation of the serine residue in the protease catalytic triad. We demonstrate that this fXa variant retains the capacity to bind direct fXa inhibitors. In addition, r-Antidote also binds to LMWH or pentasaccharide-activated ATIII and modulates the activity of these indirect fXa inhibitors. The recombinant protein was expressed in its mature, functional form and not as a zymogen. We report proof-of-concept results for this universal antidote for the reversal of anticoagulation by fXa inhibitors in vitro and in animal models of bleeding.
RESULTS

Expression and purification of r-Antidote
A schematic of the r-Antidote molecule (Fig. 1a) shows the three modifications to native fX, resulting in a protein that can bind to fXa inhibitors and counteract their activity but is no longer capable of assembly into the prothrombinase complex. We expressed r-Antidote in Chinese hamster ovary (CHO) cells and purified it from conditioned medium. The two-step purification procedure yielded purified proteins of the expected molecular weight for the light (~11 kDa) and heavy (~28 kDa) chains (Fig. 1b) . Deletion of 34 residues in the light chain of native fX (residues 46-78) resulted in a lower molecular weight for the r-Antidote light chain compared to plasma-derived fXa. The double bands observed for the heavy chain of both plasmaderived fXa and r-Antidote correspond to the α-and β-isoforms of the protein. The β-isoform results from additional proteolytic cleavage at the C terminus of the heavy chain 11, 12 . We verified the identity of the heavy and light chains of the purified proteins by western blotting with human fX-and Xa-specific monoclonal antibodies (data not shown). N-terminal sequencing of both the light and heavy chains of purified r-Antidote yielded the expected amino acid sequences, indicating proper processing of the PrePro sequence at the N-terminus of the light chain and the RKRRKR linker at the N-terminus of the heavy chain (data not shown). To produce functional protein, proper processing requires that the N terminus of the heavy chain start at Ile235 and the RKRRKR linker be completely removed.
Reversal of direct fXa inhibitors by r-Antidote
We determined the potency (K d ) of r-Antidote binding to three direct fXa inhibitors (betrixaban, rivaroxaban and apixaban) and compared them to inhibition of purified human fXa using a peptidyl substrate (Fig. 2a) . r-Antidote dose-dependently reversed the inhibitory activity of the small-molecule fXa inhibitors but did not produce any change in the rate of peptidyl substrate cleavage by fXa in the absence of inhibitor. This observation is consistent with the expected lack of catalytic activity of r-Antidote. Analysis of these kinetic data indicated that r-Antidote has subnanomolar affinities for these direct fXa inhibitors ( Table 1) . The relative potency of binding was in the same order of magnitude as the inhibition constants (K i ) reported in the literature for these inhibitors against plasma-derived fXa [13] [14] [15] .
After testing in a purified enzyme system, we evaluated the ability of r-Antidote to reverse the effects of anticoagulation in plasma. We determined the residual inhibitory activity of rivaroxaban, as measured by anti-fXa activity, after incubation with varying amounts of r-Antidote. Inhibitory activity was dose-dependently and completely reversed by r-Antidote in both human and rat plasma (data not shown). We next used rivaroxaban as a prototype inhibitor to test the effects of r-Antidote on markers of anticoagulation as measured npg by ex vivo clotting assays. r-Antidote reversed the anticoagulant effect of rivaroxaban in human plasma (Fig. 2b) . At a near-peak therapeutic concentration, rivaroxaban (1 µM) caused a prolongation of prothrombin time. This prolongation was corrected to baseline by an approximately equal molar concentration of r-Antidote. Although r-Antidote bound and neutralized the anticoagulant effect of rivaroxaban in a dose-dependent manner, r-Antidote by itself did not change prothrombin time at the highest concentration tested (Fig. 2b) . Thus, r-Antidote alone did not produce detectable amounts of procoagulant or anticoagulant activity as measured by this clotting assay.
As an additional test of the procoagulant or anticoagulant activity of r-Antidote, we used a thrombin generation assay, which tests fXa activity in the presence of cofactor factor Va and phospholipids in the prothrombinase complex. r-Antidote lacks the GLA domain and should have a substantially reduced capacity to incorporate into the prothrombinase complex. In contrast, active site-inhibited fXa with an intact GLA domain is expected to be a potent anticoagulant, as it can compete with endogenous fXa for assembly into the prothrombinase complex. We compared the effect of r-Antidote on prothrombinase activity with that of EGR-Xa, an active site-inhibited full-length human fXa. We measured prothrombinase activity by thrombin generation in human plasma with increasing concentrations of r-Antidote (0-3.3 µM) or EGR-Xa (0-0.5 µM). Formation of thrombin (as measured by relative fluorescence units) in the presence of r-Antidote remained essentially unchanged up to a concentration of 3.3 µM, whereas EGR-Xa showed potent inhibition in the same assay (half-maximal inhibitory concentration of 26 nM) (Fig. 2c) . These results are consistent with an earlier report documenting inhibition of prothrombinase activity by active site-inhibited native fXa 16 .
We next tested the ability of r-Antidote to reverse the anticoagulant effect of three direct fXa inhibitors in vivo in a rat model. Infusion of rivaroxaban (0.25 mg per kg body weight h −1 ) over a 30-min period produced a twofold increase in the level of anticoagulation as measured by whole-blood INR (international normalized ratio) (Fig. 3a) . After rivaroxaban infusion was stopped, rats were treated with vehicle or were given an intravenous (i.v.) bolus injection of r-Antidote (4 mg per rat) followed by sustained r-Antidote infusion (4 mg h −1 ). In the vehicle-treated group, INR values decreased gradually as a result of clearance of the circulating inhibitor. In contrast, in the r-Antidotetreated group, the raised INR was rapidly and completely reversed to baseline values, and this reversal was sustained.
We also evaluated the effect of r-Antidote administration on the pharmacokinetics of rivaroxaban (Supplementary Fig. 1 ). After i.v. administration of r-Antidote, the total rivaroxaban plasma concentration increased immediately as a result of the redistribution of rivaroxaban from extravascular compartments. Despite the increase in total rivaroxaban concentration, the amount of free, non-protein bound rivaroxaban (the fraction responsible for anticoagulant activity) decreased to very low levels. Thus, a decrease in the free fraction of rivaroxaban correlated with the correction of whole-blood INR values. The plasma molar ratios of r-Antidote to rivaroxaban (total) during the experimental time course were 2.1 (35 min), 1.7 (60 min) and 1.3 (90 min). As the plasma molar ratio of r-Antidote to fXa inhibitor decreased during the time course, some reestablishment of anticoagulation was observed in the rats.
We next performed similar experiments testing the effects of r-Antidote after betrixaban and apixaban infusion into rats (Fig. 3b,c) . As above, we collected serial blood samples to measure whole-blood INR values, plasma concentrations of r-Antidote and the total and free plasma fractions of the inhibitors. Both betrixaban and apixaban-mediated whole-blood INR increases were similarly reversed by r-Antidote. After i.v. infusion of the three fXa inhibitors (each administered individually) for 30 min, the total plasma concentrations of rivaroxaban, betrixaban and apixaban were 1.4 ± 0.4 µM (mean ± s.d.), 0.2 ± 0.01 µM and 1.4 ± 0.3 µM, respectively, and the percentages of unbound inhibitor were 2.2% ± 0.8% (mean ± s.d.), 40% ± 7.2% and 1.5% ± 0.3%, respectively. After administration of r-Antidote, the total plasma concentrations of the inhibitors increased to 1.9 ± 0.09 µM, 2.0 ± 0.4 µM and 4.2 ± 0.7 µM, respectively, and the percentage of unbound inhibitor declined to 0%, 0.3% ± 0.1% and 0.05% ± 0.02%, respectively. Thus, for each of the three inhibitors, correction of prothrombin time by r-Antidote to near-normal values was associated with a reduction in the free fraction of the inhibitor.
r-Antidote restores hemostasis in animal models of blood loss To evaluate whether effects of r-Antidote in reversing coagulation as measured by INR translates into a cessation of bleeding, we first tested the ability of r-Antidote to restore normal hemostasis in a mouse Figure 2a with the reported K i value for each inhibitor. Fig. 2 ; 216 ± 222 µl (mean ± s.d.) as compared to 86 ± 79 µl for vehicle treated controls (P = 0.14)). Aspirin (ASA) monotherapy at an oral dose of ~100 mg per kg body weight d −1 for 5 d did not result in a statistically significant increase in blood loss (118 ± 71 µl compared to 86 ± 79 µl for vehicle-treated controls, P = 0.48). However, combination of the 5-day ASA treatment with a single oral dose of rivaroxaban at 50 mg per kg body weight increased blood loss by 3.4-fold (403 ± 107 µl) compared to treatment with ASA alone. An i.v. injection of r-Antidote (0.96 mg per mouse) 2 h after administration of the oral dose of rivaroxaban reduced the increased blood loss by ~84% (163 ± 82 µl) relative to rivaroxaban and ASA treatment. The effect of r-Antidote on circulating rivaroxaban concentrations was similar to our previous observations in the rat. After r-Antidote administration, the total rivaroxaban concentration in plasma was increased by 7.8-fold (data not shown). In parallel to the reduction in blood loss, rivaroxaban anticoagulant activity was reduced by >80% as measured by plasma anti-fXa activity (data not shown).
As tail transection in mice or rats may not be representative of anticoagulant-induced bleeding after major trauma and as fXa inhibitors are often used as monotherapy in the absence of aspirin, we further investigated the potential for restoration of hemostasis by r-Antidote in a rabbit model of liver laceration. We administered vehicle or 1 mg per kg body weight rivaroxaban by i.v. bolus injection to anesthetized rabbits. After 30 min to allow for biodistribution of the inhibitor, we administered vehicle or r-Antidote (75 mg per rabbit) as a bolus injection. We then lacerated two liver lobes and collected the lost blood on a preweighed gauze over 15 min. Blood loss caused by rivaroxaban anticoagulation represented approximately 10% of the total blood volume of the rabbits (Fig. 4) . As in the rodent models, we measured total and free rivaroxaban plasma concentrations, plasma anti-fXa activity, prothrombin time and activated partial thromboplastin time (aPTT).
After its administration, the circulating concentration of rivaroxaban was 1.65 ± 0.5 µM at 30 min, resulting in a 2.3-fold and a 1.9-fold prolongation of prothrombin time and aPTT, respectively, and a 3.2-fold increase in blood loss compared to vehicle treatment. Administration of r-Antidote reduced blood loss by >85% and decreased peak anti-fXa activity by 98%, prothrombin time by 74% and aPTT by 66% and altered the non-protein bound fraction of rivaroxaban in plasma from 26% ± 0.9% to 0.5% ± 0.3%. r-Antidote treatment alone had no effect on blood loss. Similarly to the rodent model (Fig. 3) , the correction of rabbit visceral blood loss by r-Antidote correlated with a reduction in anti-fXa activity and in the free fraction of direct fXa inhibitor.
Reversal of ATIII-dependent fXa inhibitors by r-Antidote r-Antidote, with a binding site mimicking that of native fXa, should have the capacity to interact with ATIII. Enoxaparin (LMWH) and fondaparinux (a pentasaccharide) increase the affinity of ATIII for fXa. Therefore, we tested the effect of r-Antidote on the anticoagulant npg activities of enoxaparin and fondaparinux. The anti-fXa activities of therapeutic amounts of enoxaparin and fondaparinux were dosedependently reversed after incubation with r-Antidote in either human or rat plasma (Supplementary Fig. 3a,b) . To further investigate the specific interaction between r-Antidote and ATIII, we measured the kinetics of inhibition in a reconstituted system with purified human proteins (fXa and ATIII) and fondaparinux. r-Antidote reduced the rate of fXa inhibition by the ATIII-fondaparinux complex in a dose-dependent manner (Supplementary Fig. 4a ). Nonlinear fitting of the experimental data with a single exponential decay function yielded an apparent association rate constant (k obs ) for the reaction.
In the absence of fondaparinux, r-Antidote had a minimal effect on the inhibition of fXa by ATIII (data not shown). r-Antidote had an enhanced binding affinity to the ATIII-fondaparinux complex as compared to ATIII alone (Supplementary Fig 4b) . The dissociation constant for the r-Antidote-ATIII-fondaparinux complex was 53 nM.
A similar high-affinity interaction between an active site-modified human fXa mutant and ATIII-pentasaccharide complex has been previously reported 17 .
We next tested the ability of r-Antidote to restore hemostasis in a rat tail transection model after treatment with enoxaparin or fondaparinux. Unlike rivaroxaban, administration of enoxaparin or fondaparinux without concomitant administration of an antiplatelet agent was sufficient to establish a reproducible pattern of bleeding in the rats. We evaluated two different doses of r-Antidote for reversal of blood loss after the same enoxaparin dose (Fig. 5a) . r-Antidote treatment at 4 mg per rat bolus plus 4 mg h −1 infusion completely corrected the increase in blood loss to baseline, whereas a lower dose of r-Antidote (2 mg per rat bolus plus 2 mg h −1 infusion) resulted in a partial (42%) correction in blood loss. In parallel to the reduction in blood loss, anti-fXa activity was reduced in a dose-dependent manner (data not shown).
As LMWH, such as enoxaparin, have both anti-fXa and antithrombin inhibitory activities, we investigated fondaparinux, a fXa-specific indirect inhibitor in the rat tail transection model. Supratherapeutic doses of fondaparinux (25 mg per kg body weight) were required to produce a statistically significant increase in blood loss (Fig. 5b) . Administration of r-Antidote produced a complete cessation of bleeding. In parallel, r-Antidote also substantially reduced the anti-fXa activity of fondaparinux (Fig. 5c) . Protamine is not expected to reverse the activity of fondaparinux. Accordingly, the tested dose of protamine (0.9 mg per rat) had no statistically significant effect on fondaparinux-induced anticoagulation (P = 0.39) (Fig. 5b) .
DISCUSSION
As part of the prothrombinase complex, fXa is the key enzyme responsible for thrombin generation in the vasculature. Although fXa in solution has low catalytic activity toward cleaving its macromolecular substrate prothrombin, this procoagulant activity is increased 300,000-fold when it is assembled with fVa in the presence of Ca 2+ into the prothrombinase complex 18 . As thrombin is the major enzyme responsible for both clot formation and platelet aggregation, reduction in thrombin generation and activity leads to therapeutic benefit in thrombotic diseases, and fXa inhibitors have been approved as a new generation of anticoagulants 1, 2 .
The structural modifications that we made to fX to generate the r-Antidote molecule were designed to retain the active site-binding pocket to allow for the binding of small-molecule fXa inhibitors. To eliminate the possibility of thrombin generation caused by the proteolytic cleavage of prothrombin, we disrupted the catalytic triad by mutation of the serine residue. Because active site-mutated full-length fXa has the potential to bind fVa and act as a competitive inhibitor of the prothrombinase complex, we also deleted the membranebinding GLA domain. The recombinant protein was expressed in its functional form and could thus be purified from harvested cell culture fluid without additional activation steps by fVIIa or fIXa.
We demonstrated both in vitro and in vivo that r-Antidote does not interfere with normal fXa function in hemostasis and does not have anticoagulant activity, as demonstrated by its lack of interference in tissue factor-initiated thrombin generation assays and in traditional clotting assays. However, on the basis of kinetic measurements, r-Antidote retains a binding site that is capable of binding direct fXa inhibitors with affinities comparable to those of native fXa. r-Antidote also binds to pentasaccharide-activated ATIII, as shown in assays using purified proteins. It should be noted that r-Antidote has potential interactions with other proteins that may not have been uncovered in the in vitro experimental systems or the animal models studied here. On the basis of reported interactions of native fX and Xa, r-Antidote might interact with circulating ATIII (even in the absence of heparin-like moieties), tissue factor pathway inhibitor, factor V or protein S or protein Z inhibitor. Although we did not detect effects of r-Antidote on signaling by protease-activated receptor 2 in cell lines expressing this receptor (S. Delaney, Portola Pharmaceuticals, personal communication), the possibility exists that the in vitro system used is not sensitive enough to detect changes that may be important in primary cells.
To bypass the need for its activation through intrinsic or extrinsic pathways of coagulation, we expressed r-Antidote in its mature, functional form in CHO cells. However, the use of a recombinant human protein variant, albeit with a conserved N-terminal amino acid sequence of the native protein, has the potential for immunogenicity. Studies in which r-Antidote is administered repeatedly to patients with long-term follow up will be needed to address concerns regarding the generation of r-Antidote-specific antibodies or crossreactive antibodies to native fX or fXa.
The anticoagulant activity of LMWH and fondaparinux is mediated by ATIII, which is an irreversible inhibitor of serine proteases of the coagulation cascade. Under physiologic conditions, inhibition of fXa by ATIII proceeds at a slow rate. However, as our results and those in the literature show, the rate of inhibition is greatly enhanced in the presence of heparin-like polysaccharides 19, 20 . Although protamine is used for the neutralization of unfractionated heparin, it only partially reverses the anticoagulant activity of LMWH and has no effect on fondaparinux 5, [21] [22] [23] [24] . Additionally, concerns about the potential side effects of protamine, such as allergic reactions, have limited its use in the clinical setting. Synthetic small-molecule salicylamide derivatives have been proposed for the neutralization of heparin and LMWH 25 . Modified ATIII mutants have also been used as reversal agents for ATIII-dependent anticoagulants 26 . None of these agents is currently indicated for use in patients.
The mechanism of action of r-Antidote is different from the approaches discussed above. Because r-Antidote still has the fXa active site, albeit without the catalytic serine residue, the protein can compete with fXa to bind to ATIII in the ATIII-heparin complex. Administration of r-Antidote reduces the effective concentration of the ATIII-heparin complex, reversing the anticoagulant effect of ATIII-dependent fXa inhibitors. An advantage of targeting the complex over either ATIII or the anticoagulant saccharide is that the complex is the rate-limiting component in the inhibition pathway, npg implying that lower circulating concentrations of r-Antidote would be needed to sustain reversal of anticoagulation.
Recent trials in large numbers of patients using direct fXa inhibitors for the prevention of deep vein thrombosis and atrial fibrillation have demonstrated efficacy in these clinical settings but have also shown that bleeding is the major safety concern with these promising new agents 27 . A recent report of the reversal of rivaroxaban anticoagulation in healthy volunteers using prothrombin-complex concentrate used surrogate markers to monitor the reversal of anticoagulation and did not demonstrate a reduction in bleeding 28 .
We presume that after dosing into an animal previously treated with a direct fXa inhibitor, r-Antidote binds immediately to the inhibitor and thereby reduces the non-protein bound free fraction of the inhibitor. Thus, the anticoagulant effect caused by a direct fXa inhibitor is neutralized by administration of r-Antidote. We demonstrated the rapid onset of action for r-Antidote to bind and neutralize this class of inhibitors in animals treated with rivaroxaban, betrixaban and apixaban. The effect of r-Antidote in reducing the free plasma concentrations of direct fXa inhibitors is analogous to that of DigiFab, which reduces the free concentration of digoxin and reverses digoxin toxicity 29 . However, it is difficult to extrapolate animal model data to estimate what dose of r-Antidote would be needed in humans. By necessity, the animal models are stringent and use very high doses of fXa inhibitors to produce reproducible blood loss. Also, the extent of reversal of anticoagulation in patients that is necessary to restore hemostasis will be dependent on circulating concentrations of fXa inhibitor, as well as other factors (for example, renal clearance and concomitant medications).
We have established the ability of r-Antidote to reverse the anticoagulant activity of fXa inhibitors and restore hemostasis in anticoagulated animals. The capacity of r-Antidote to reverse both direct and indirect fXa inhibitors demonstrates its potential as an effective universal antidote for current and emerging anticoagulants for patients suffering major bleeding or requiring elective surgery.
METhODS
Methods and any associated references are available in the online version of the paper. 
